Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

Identifieur interne : 002224 ( PubMed/Corpus ); précédent : 002223; suivant : 002225

Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

Auteurs : Yuxian He ; Jingjing Li ; Susanne Heck ; Sara Lustigman ; Shibo Jiang

Source :

RBID : pubmed:16731915

English descriptors

Abstract

The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.

DOI: 10.1128/JVI.00083-06
PubMed: 16731915

Links to Exploration step

pubmed:16731915

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.</title>
<author>
<name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
<affiliation>
<nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA. yhe@NYBloodcenter.org</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Li, Jingjing" sort="Li, Jingjing" uniqKey="Li J" first="Jingjing" last="Li">Jingjing Li</name>
</author>
<author>
<name sortKey="Heck, Susanne" sort="Heck, Susanne" uniqKey="Heck S" first="Susanne" last="Heck">Susanne Heck</name>
</author>
<author>
<name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name>
</author>
<author>
<name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16731915</idno>
<idno type="pmid">16731915</idno>
<idno type="doi">10.1128/JVI.00083-06</idno>
<idno type="wicri:Area/PubMed/Corpus">002224</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002224</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.</title>
<author>
<name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name>
<affiliation>
<nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA. yhe@NYBloodcenter.org</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Li, Jingjing" sort="Li, Jingjing" uniqKey="Li J" first="Jingjing" last="Li">Jingjing Li</name>
</author>
<author>
<name sortKey="Heck, Susanne" sort="Heck, Susanne" uniqKey="Heck S" first="Susanne" last="Heck">Susanne Heck</name>
</author>
<author>
<name sortKey="Lustigman, Sara" sort="Lustigman, Sara" uniqKey="Lustigman S" first="Sara" last="Lustigman">Sara Lustigman</name>
</author>
<author>
<name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint>
<date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antibodies, Monoclonal</term>
<term>Antibodies, Viral (biosynthesis)</term>
<term>Antibody Formation (drug effects)</term>
<term>Antigens, Viral</term>
<term>Baculoviridae (genetics)</term>
<term>Cloning, Molecular</term>
<term>Epitope Mapping</term>
<term>Humans</term>
<term>Immunization</term>
<term>Membrane Glycoproteins (administration & dosage)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Membrane Glycoproteins (therapeutic use)</term>
<term>Mice</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (administration & dosage)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Envelope Proteins (therapeutic use)</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en">
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Antibodies, Monoclonal</term>
<term>Antigens, Viral</term>
<term>Recombinant Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Antibody Formation</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Baculoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cloning, Molecular</term>
<term>Epitope Mapping</term>
<term>Humans</term>
<term>Immunization</term>
<term>Mice</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">16731915</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>08</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>80</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2006</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.</ArticleTitle>
<Pagination>
<MedlinePgn>5757-67</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Yuxian</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA. yhe@NYBloodcenter.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jingjing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heck</LastName>
<ForeName>Susanne</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lustigman</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Shibo</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>5</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>5</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16731915</ArticleId>
<ArticleId IdType="pii">80/12/5757</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.00083-06</ArticleId>
<ArticleId IdType="pmc">PMC1472569</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16169905</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16166518</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2001 Jan 20;279(2):371-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11162792</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12748314</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2003 May 29;423(6939):467</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12774078</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2003 Dec 12;115(6):652-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14675530</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2004 Jan 30;314(1):235-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14715271</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14670965</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Feb 13;303(5660):944-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14963300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15043961</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 May;78(9):4552-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15078936</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14996844</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 May 21;304(5674):1097</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15155925</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15150417</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8709-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15161975</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 Jul;78(13):6938-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15194770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 Jul;78(13):7217-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15194798</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2004 Jun 26;363(9427):2122-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15220033</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15220038</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15210961</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>DNA Cell Biol. 2005 Aug;24(8):510-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16101349</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Viral Immunol. 2005;18(2):327-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16035944</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2004 Sep 15;173(6):4050-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15356154</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 Oct;78(19):10628-35</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15367630</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Microbiol. 2004 Oct;12(10):466-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15381196</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15474494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2004 Oct;10(10):1774-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15504263</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15530413</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2005 Feb;79(3):1635-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15650189</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15695582</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2005 Mar;79(6):3289-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15731223</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2005 Mar 30;334(1):74-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15749124</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2005 Apr 15;174(8):4908-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15814718</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15791205</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2005 Jul;11(7):1016-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16022774</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2005 Nov;79(22):13915-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16254327</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002224 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002224 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:16731915
   |texte=   Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:16731915" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021